SEBASTIAN STINTZING, M.D

“My main focus is to optimize the treatment for patients with GI malignancies. Clinical studies I coordinate usually compare approved substances against each other or evaluate them in untested sequences. Additionally, data and biomaterial from these studies are used for the development of clinical and molecular markers to further individualize our patients´ treatment. Arfolitixorin is a new substance which will hopefully increase the efficacy of the long established FOLFOX regimen without adding toxicity”.

Sebastian Stintzing M.D., is Professor of Medicine and Head of the Division of Haematology, Oncology, and Tumor Immunology (CCM), Department of Medicine at Charité Universitaetsmedizin Berlin. His research focuses on predictive and prognostic biomarkers in the treatment of GI cancer with a special focus on colorectal cancer. He is a member of various national and international cancer associations and speaker of the steering committee of the working group of Colorectal Carcinoma of the German AIO. He coordinates several multicentre and international investigator initiated studies. He earned his Postdoctoral Lecture Qualification with a thesis on prognostic and predictive factors in the treatment of metastatic colorectal cancer.